Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 17;30(8):1809.
doi: 10.3390/molecules30081809.

Discovery of Lignans from the Herbs of Peperomia heyneana with Inhibitory Activities on BPH-1 Cells

Affiliations

Discovery of Lignans from the Herbs of Peperomia heyneana with Inhibitory Activities on BPH-1 Cells

Yufei Xi et al. Molecules. .

Abstract

Chemical investigation on the whole herb of Peperomia heyneana Miq. resulted in the isolation of six lignans, including two previously undescribed compounds, named peperomianan A and B (1-2), and four known compounds, 1,2-cyclobutanedicarboxylic acid (3), (+)-medioresinol (4), (+)-pinoresinol (5), and (+)-yangambin (6). Their structures were established by extensive spectroscopic analyses. The absolute configuration of compound 1 was determined by comparison of the experimental and calculated electronic circular dichroism (ECD) spectra. Subsequently, the effects of all isolates on BPH-1 cells were evaluated in vitro by MTT assay.

Keywords: BPH; Peperomia heyneana; lignans; structure elucidation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Key HMBCs for compounds 1 and 2.
Figure 2
Figure 2
Calculated and experimental ECD spectra of 1.
Figure 3
Figure 3
Key NOESY correlation (arrows, from 1H to 1H) of compound 2.
Figure 4
Figure 4
The structures of compounds 16.
Figure 5
Figure 5
Cytotoxicity assay of compounds 1–6 on BPH-1 cells. Cell viabilities were determined by MTT assay in the presence of positive control (Finasteride) and the tested compounds at different concentrations (12.5, 25, 50, 100, 200, 400 μM). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared with positive control.

Similar articles

References

    1. Zabbarova I.V., Ikeda Y., Kozlowski M.G., Tyagi P., Birder L.A., Chakrabarty B., Perera S.K., Dhir R., Straub A.C., Sandner P., et al. Benign prostatic hyperplasia/obstruction ameliorated using a soluble guanylate cyclase activator. J. Pathol. 2022;256:442–454. doi: 10.1002/path.5859. - DOI - PMC - PubMed
    1. Stephen S.C., John M.F. Medical treatment of benign prostatic hyperplasia. Postgrad Med. J. 2007;83:73–78. - PMC - PubMed
    1. Wang X.P. Network meta-analysis of the efficacy of α adrenergic receptor antagonists in the treatment of BPH drugs. Chin. J. Androl. 2018;24:247–253. - PubMed
    1. Infante G.E.P., Samain M.S., Castillo J.A.A., Collazos L.E.A.A. Species of Peperomia (Piperaceae) from the Saña River Valley, Peru. PhytoKeys. 2023;225:1–40. doi: 10.3897/phytokeys.225.99277. - DOI - PMC - PubMed
    1. Shu C.H.J. Peperomia (Ruiz & Pavon, Fl. Peruv. Prodr. 8: 8. 1794) Flora China. 1999;4:129–131.

LinkOut - more resources